Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) Attends 31st Annual ROTH Conference
Conatus Pharmaceuticals (NASDAQ: CNAT) is a biotechnology company focused on the development of novel medicines to treat liver disease. In collaboration with Novartis, Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is a first-in-class, orally active pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, caspase inhibitors have the potential to interrupt the progression of a variety of diseases. For more information, visit the company's website at www.conatuspharma.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news…







